Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- New Nord Family Greenway profiled in “Architect Magazine”
- Distinguished University Professor Richard Boyatzis weighs in on research suggesting emotions can be spread from person to person
- Music’s David Rothenberg previews The Cleveland Orchestra’s performance of Dvorak’s Stabat Mater
- PRCHN’s Darcy Freedman discusses Future of Food in Your Neighborhood Study
- Collegiate Inventors Competition accepting applications through June 1